NEW YORK (GenomeWeb News) – Veracyte said after the close of the market on Monday that revenues in its third quarter improved 75 percent year over year.

The South San Francisco, Calif.-based company, which went public earlier this month, raising $58 million in net proceeds, reported revenues of $5.6 million for the three months ended Sept. 30, up from $3.2 million in the year-ago period.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

The New York Times editorial board weighs in on scientific research misconduct.